Results 51 to 60 of about 80,266 (330)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer

Frontiers in Cell and Developmental Biology, 2021
Bruton’s tyrosine kinase (BTK) is a soluble tyrosine kinase with central roles in the development, maturation, and signaling of B cells. BTK has been found to regulate cell proliferation, survival, and migration in various B-cell malignancies.
Xianhui Wang, Leila Kokabee, Mostafa Kokabee, Douglas S. Conklin   +3 more
doaj   +1 more source

Btk inhibitors in atherosclerosis [PDF]

Blood, 2018
In this issue of Blood, Busygina et al provide provocative evidence that there is a potential role for Bruton tyrosine kinase (Btk) inhibitors in inhibiting platelet aggregation specifically at the site of unstable atherosclerotic plaques ...
openaire   +2 more sources

Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity [PDF]

, 2005
During B-cell development in the mouse, Bruton tyrosine kinase (Btk) and the adaptor protein SLP-65 (Src homology 2 [SH2] domain-containing leukocyte protein of 65 kDa) limit the expansion and promote the differentiation of pre-B cells.
Dingjan, G.M. (Gemma), Hendriks, R.W. (Rudi), Jumaa, H., Kersseboom, R. (Rogier), Middendorp, S., Zijlstra, A.J.E. (Esther)   +5 more
core   +3 more sources

BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects

Frontiers in Immunology, 2021
Bruton´s tyrosine kinase (BTK) inhibitor (BTKi)s block the B-cell receptor (BCR) signaling cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant and normal B cells.
M. Palma, T. Mulder, A. Österborg
semanticscholar   +1 more source

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus

Frontiers in Medicine, 2021
Bruton Tyrosine Kinase (BTK) has a key role in multiple pathways involved in inflammation and autoimmunity. Therefore, BTK has become a new therapeutic target for a group of hematologic and autoimmune disorders.
Aikaterini Patsatsi, Dedee F. Murrell
doaj   +1 more source

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Science
Increasing use of covalent and noncovalent inhibitors of Bruton’s tyrosine kinase (BTK) has elucidated a series of acquired drug-resistant BTK mutations in patients with B cell malignancies.
S. Montoya, J. Bourcier, M. Noviski, Hao Lu, Meghan C. Thompson, Alexandra Chirino, J. Jahn, Anya K. Sondhi, Stefan Gajewski, Ying Siow (May) Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, C. Guiducci, James N. Iuliano, Tim Kane, Ratul Mukerji, P. J. Reddy, Janine Powers, Mateo Sanchez Garcia de los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, R. Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, T. Totiger, Camila Pena-Velasquez, Joanna M. Rhodes, A. Zelenetz, Alvaro J Alencar, L. Roeker, Sanjoy Mehta, Ralph Garippa, A. Linley, R. Soni, Sigrid S. Skånland, Robert J. Brown, A. Mato, Gwenn H. Hansen, Omar Abdel-Wahab, Justin Taylor   +52 more
semanticscholar   +1 more source

Coexistence of two order parameters and a pseudogaplike feature in the iron-based superconductor LaFeAsO_(1-x)F_x [PDF]

, 2009
The nature and value of the order parameters (OPs) in the superconducting Fe-based oxypnictides REFeAsO_(1-x)F_x (RE = rare earth) are a matter of intense debate, also connected to the pairing mechanism which is probably unconventional.
Daghero, D., Gonnelli, R. S., Kim, J. S., Kremer, R. K., Stepanov, V. A., Tortello, M., Ummarino, G. A.   +6 more
core   +1 more source

Managing Waldenström’s macroglobulinemia with BTK inhibitors

Leukemia, 2022
Bruton’s tyrosine kinase (BTK) inhibition is one of the treatment standards for patients with relapsed/refractory Waldenström’s macroglobulinemia (WM) and for patients with WM who are unsuitable for immunochemotherapy (ICT).
C. Buske, W. Jurczak, J. Salem, M. Dimopoulos   +3 more
semanticscholar   +1 more source

BTK inhibitors in CLL: second-generation drugs and beyond

Blood Advances
BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia.
Constantine S. Tam, Philip A Thompson
semanticscholar   +1 more source